Monopar Therapeutics Inc. (MNPR)
$77.05-2.42%Close
SELLCRISIS · day 19
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $516M
- Beta
- 1.51
- P/E (TTM)
- -34.00
- Short % float
- 26.09%
- Days to cover
- 6.0
- SI change
- +28.7%
- 1W
- -1.58%
- 1M
- -30.12%
- vs SPY 1W
- -2.01%
- vs SPY 1M
- -32.18%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 19
- VALUE
- 8
- GROWTH
- 47
- GARP
- 6
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-7.8%
REV YoY-
ROE-13.1%
EPS YoY-
ROA-13.2%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-34.00
P/E FWD-
SECTOR PE20.54
INDUSTRY PE14.03
P/B5.19
P/FCF-
EV/EBITDA-25.97
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E0.08
ALTMAN Z-
CURR RATIO33.56
ND/EBITDA-
BETA1.51
Company news
FAQ
- What is LOPJLB’s current signal on MNPR?
- LOPJLB’s latest quantitative signal on Monopar Therapeutics Inc. (MNPR) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is MNPR in?
- Monopar Therapeutics Inc. (MNPR) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Monopar Therapeutics Inc. (MNPR) do?
- Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expre…